Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors, in previously treated advanced G12C-mutated non-small cell lung cancer
Patient-reported outcomes from Phase III lidERA study showed improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancer
Second Phase III results in Chinese patients with metastatic nasopharyngeal carcinoma demonstrate the potential of Tam-Peli, a next-generation B7-H3 targeted ADC, to deliver robust efficacy with a favorable safety pro high-unmet-need solid tumors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
$RHHBY
--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, held from October 23 to 27 in Madrid.
“Our presentations at ESMO 2026 highlight the depth and impact of Genentech’s oncology pipeline, driven by emerging science capable of bringing new treatment benefits across diverse and high-unmet-need cancers,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “From establishing head-to-head superiority with divarasib in KRAS G12C-mutated lung cancer to advancing patient-centered oral SERD therapies like giredestrant and next-generation ADCs such as Tam-Peli, we are committed to delivering medicines that not only extend life, but also seek to improve treatment experience, tolerability and quality of life for people living with cancer.”
Divarasib demonstrated superior efficacy and best-in-class potential in KRAS G12C NSCLC
Genentech will share Phase III Krascendo 1 results, which demonstrated divarasib’s best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer.
Krascendo 1 is the only global head-to-head trial to evaluate a next-generation KRAS G12C inhibitor versus approved first-generation inhibitors.
Results
for this potential best-in-class, next-generation KRAS G12C-targeted therapy
will be presented as a late-breaking abstract during a Presidential Symposium.
Giredestrant data support its potential to become the new standard of care in early-stage and advanced breast cancer
Genentech will present new data highlighting the potential role of giredestrant, an investigational, oral, potent next-generation selective estrogen receptor degrader (SERD) and full antagonist, in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, a subtype in which more than 90% of cases are diagnosed at an early stage (I-III). Key presentations from early-stage to advanced disease include:
Patient-reported outcomes from the Phase III lidERA Breast Cancer trial suggesting that the improved efficacy of giredestrant compared to endocrine therapy is achieved without compromising tolerability or Health-Related Quality of Life.
Exploratory biomarker findings from the evERA Breast Cancer trial of giredestrant in combination with everolimus in ER-positive, HER2-negative advanced breast cancer in the post-cyclin-dependent kinase 4/6 inhibitor setting.
Updated interim results for giredestrant plus inavolisib from the MORPHEUS Breast Cancer trial evaluating giredestrant treatment combinations in ER-positive, HER2-negative locally advanced or metastatic breast cancer.
Data demonstrate the potential of a next generation B7-H3 targeted antibody-drug conjugate (ADC) Tam-Peli (tambotatug pelitecan)
New data will also be presented for Tam-Peli, an investigational next-generation B7-H3-targeted ADC designed to deliver high-potency anti-tumor activity while limiting off-target toxicity. Tam-Peli is currently being investigated across multiple solid tumor indications:
ESMO data include late-breaking interim Phase III results in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma, analyses of interstitial lung disease in patients with advanced solid tumors from Phase I/II studies, and Phase I efficacy and safety data for Tam-Peli in patients with locally advanced or metastatic NSCLC.
These findings build on the TAISHAN-302 Phase III data in second-line small cell lung cancer presented at the World Conference on Lung Cancer in September, where the study met all three specified endpoints of overall survival, progression free survival and objective response rate at its first interim analysis.
Roche is developing and commercializing Tam-Peli outside mainland China, Hong Kong, and Macau, and plans to rapidly initiate global trials across multiple tumor types.
Overview of key presentations featuring Genentech medicines and molecules:
Medicine or molecule
Abstract title
Abstract number/ presentation details
Lung cancer
Divarasib
Krascendo 1: Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC.
#LBA5 Proffered Paper Session
Presidential Symposium II
Sunday 10.25.2026
16:30 - 16:42 CET
Divarasib
Krascendo 3: A randomized, Phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer.
#2551 TiP Poster
NSCLC, Early-Stage
Monday 10.26.2026
12:00 – 12:45 CET
Tam-Peli
Tambotatug pelitecan (YL201): Efficacy and safety in locally advanced/ metastatic NSCLC from a Phase I study.
#2577 Poster
NSCLC, Locally Advanced
Monday 10.26.2026
12:00 – 12:45 CET
Non-specific
Immunogenomic signature associated with ICI-related pneumonitis in non-small-cell lung cancer (NSCLC) patients.
#4247 Rapid Oral
Basic Science and Translational Research
Sunday 10.25.2026
09:14 - 09:19 CET
Breast cancer
Giredestrant
Patient (pt)-reported outcomes (PROs) from the Phase III lidERA Breast Cancer (BC) trial of giredestrant (GIRE) in pts with estrogen receptor-positive, HER2-negative early BC (ER+, HER2− eBC).
#538 Rapid Oral
Breast Cancer, Early-Stage
Friday 10.23.2026
16:20 – 16:25 CEST
Giredestrant
Retrospective exploratory biomarker (BM) analyses from evERA Breast Cancer (BC): A Phase III trial of giredestrant (GIRE) + everolimus (E) in patients with estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2− aBC) in the post-CDK4/6 inhibitor (I) setting.
#2 Rapid Oral
Breast Cancer, Advanced Stage
Saturday 10.24.2026
10:20 – 10:25 CEST
Giredestrant
Updated interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS Breast Cancer (BC): A Phase Ib/II study of GIRE treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2− LA/mBC).
#23 Poster
Advanced Breast Cancer, Other
Saturday 10.24.2026
12:00 – 12:45 CEST
Pertuzumab
Real-world eligibility for DESTINY-Breast11 (DB-11) neoadjuvant escalation criteria and outcomes of DB-11-eligible vs DB-11-ineligible patients with HER2-positive early breast cancer (HER2+ eBC).
#594 Poster
Breast Cancer, Early-Stage
Saturday 10.24.2026
12:00 – 12:45 CEST
ZN-1041
BREnnA: Phase II/III randomized study of ZN-A-1041 or tucatinib (TUC), in combination with trastuzumab + capecitabine (HX), in patients with HER2-positive locally advanced or metastatic breast cancer (HER2+LA/mBC) with or without central nervous system (CNS) metastases.
#1796 TiP Poster
HER2+ Breast Cancer
Saturday 10.24.2026
12:00 – 12:45 CEST
Solid tumors
Tam-Peli
Tambotatug pelitecan (YL201): Analyses of interstitial lung disease in patients with advanced solid tumors from Phase I/II studies.
#1057 Poster
Developmental Therapeutics
Friday 10.23.2026
15:15 – 16:00 CEST
YL211 (cMET ADC)
Phase I First-in-Human (FIH) Results of YL211, a c-Met targeting Antibody-Drug Conjugate (ADC), in patients (pts) with advanced solid tumors.
#1017 Poster
Developmental Therapeutics
Friday 10.23.2026
15:15 – 16:00 CEST
Tam-Peli
Tam-Peli versus chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): a multicenter, randomized, open-label, Phase III study (TAISHAN-301).
#LBA43 Proffered Paper Session
Head and Neck Cancer
Sunday 10.25.2026
08:40 - 08:50 CET
Tecentriq (atezolizumab) + Avastin (bevacizumab)
Outcomes by baseline tumor burden using 6-and-12 scores and the up-to-7 criteria in TALENTACE: Phase III study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo/Bev) or on demand TACE alone in patients with systemically untreated, unresectable hepatocellular carcinoma (uHCC).
#1700 ePoster
Hepatocellular Carcinoma
Tecentriq (atezolizumab)
ATOMIC (A021502/AIO-KRK-0317): Presentation and outcomes in patients (pts) with stage III d-MMR early-onset colon cancer (EOCC) and average-onset colon cancer (AOCC).
#858 Poster
Colon Cancer
Sunday 10.25.2026
12:00 - 12:45 CET
Tecentriq (atezolizumab)
Adjuvant atezolizumab in patients with MSI-high/MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy: the Phase II ANTONIO-study (AIO-KRK-0220).
#802 Poster
Colon Cancer
Sunday 10.25.2026
12:00 - 12:45 CET
What is Itovebi?
Itovebi (inavolisib) is a prescription medicine used in combination with the medicines palbociclib and fulvestrant to treat adults who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has an abnormal phosphatidylinositol-3-kinase catalytic subunit alpha (
PIK3CA
) gene, and has spread to nearby tissue or lymph nodes (locally advanced), or to other parts of the body (metastatic), and has come back after hormone (endocrine) therapy.
Your healthcare provider will test your cancer for abnormal
PIK3CA
genes to make sure that Itovebi is right for you.
It is not known if Itovebi is safe and effective in children.
Important Safety Information
What are the possible side effects of Itovebi?
Itovebi may cause serious side effects, including:
High blood sugar levels (hyperglycemia).
High blood sugar is common with Itovebi and may be severe. Your healthcare provider will monitor your blood sugar levels before you start and during treatment with Itovebi. Your blood sugar levels may be monitored more often if you have a history of Type 2 diabetes. Your healthcare provider may also ask you to self-monitor and report your blood sugar levels at home. This will be required more frequently in the first 4 weeks of treatment. If you are not sure how to test your blood sugar levels, talk to your healthcare provider. You should stay well-hydrated during treatment with Itovebi. Tell your healthcare provider right away if you develop symptoms of high blood sugar, including:
difficulty breathing
nausea and vomiting (lasting more than 2 hours)
stomach pain
excessive thirst
dry mouth
more frequent urination than usual or a higher amount of urine than normal
blurred vision
unusually increased appetite
weight loss
fruity-smelling breath
flushed face and dry skin
feeling unusually sleepy or tired
confusion
Mouth sores (stomatitis).
Mouth sores are common with Itovebi and may be severe. Tell your healthcare provider if you develop any of the following in your mouth:
pain
swelling
redness
ulcers
Diarrhea is common with Itovebi and may be severe. Severe diarrhea can lead to the loss of too much body water (dehydration) and kidney injury. Tell your healthcare provider right away if you develop diarrhea, stomach-area (abdominal) pain, or see mucus or blood in your stool during treatment with Itovebi. Your healthcare provider may tell you to drink more fluids or take medicines to treat your diarrhea.
Your healthcare provider may tell you to decrease your dose, temporarily stop your treatment, or completely stop your treatment with Itovebi if you develop certain serious side effects.
The most common side effects and abnormal blood test results of Itovebi when used in combination with palbociclib and fulvestrant include:
decreased white blood cell counts, red blood cell counts, and platelet counts
decreased blood levels of calcium, potassium, sodium, and magnesium
increased creatinine blood levels
tiredness
increased blood levels of the liver enzyme alanine transaminase (ALT)
nausea
rash
loss of appetite
COVID-19 infection
headache
Itovebi may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.
These are not all the possible side effects of Itovebi. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or
. You may also report side effects to Genentech at (877) 436-3683.
Before you take Itovebi, tell your healthcare provider about all of your medical conditions, including if you:
have a history of diabetes or high blood sugar
have kidney problems
are pregnant or plan to become pregnant. Itovebi can harm your unborn baby.
Females who are able to become pregnant:
Your healthcare provider will check to see if you are pregnant before you start treatment with Itovebi.
You should use effective non-hormonal birth control (contraception) during treatment with Itovebi and for 1 week after your last dose. Talk to your healthcare provider about what birth control method is right for you during this time.
Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Itovebi.
Males with female partners who are able to become pregnant:
You should use effective birth control (contraception) during treatment with Itovebi and for 1 week after your last dose.
are breastfeeding or plan to breastfeed. It is not known if Itovebi passes into your breastmilk. Do not breastfeed during treatment with Itovebi and for 1 week after your last dose. Talk to your healthcare provider about the best way to feed your baby during treatment with Itovebi.
Tell your healthcare provider about all the medicines you take,
including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Please see additional Important Safety Information in the full Itovebi
Prescribing Information
or visit
.
What are Tecentriq and Tecentriq Hybreza?
Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) are prescription medicines used to treat:
Adults with a type of lung cancer called non-small cell lung cancer (NSCLC).
Tecentriq or Tecentriq Hybreza may be used alone as a treatment for your lung cancer:
to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery and you have received platinum-based chemotherapy,
and
you have stage 2 to stage 3A NSCLC (talk to your healthcare provider about what these stages mean),
and
your cancer tests positive for “PD-L1”.
Tecentriq or Tecentriq Hybreza may be used alone as your first treatment when your lung cancer:
has spread or grown,
and
your cancer tests positive for “high PD-L1”,
and
your tumor does not have an abnormal “EGFR” or “ALK” gene.
Tecentriq or Tecentriq Hybreza may be used with the medicines bevacizumab, paclitaxel, and carboplatin as your first treatment when your lung cancer:
has spread or grown,
and
is a type called “non-squamous NSCLC”,
and
your tumor does not have an abnormal “EGFR” or “ALK” gene.
Tecentriq or Tecentriq Hybreza may be used with the medicines paclitaxel protein-bound and carboplatin as your first treatment when your lung cancer:
has spread or grown,
and
is a type called “non-squamous NSCLC”,
and
your tumor does not have an abnormal “EGFR” or “ALK” gene.
Tecentriq or Tecentriq Hybreza may be used alone when your lung cancer:
has spread or grown,
and
you have tried chemotherapy that contains platinum, and it did not work or is no longer working.
If your tumor has an abnormal “EGFR” or “ALK” gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.
Adults with a type of lung cancer called “extensive stage small cell lung cancer (SCLC)”, which is SCLC that has spread or grown
Tecentriq or Tecentriq Hybreza may be used with the chemotherapy medicines carboplatin and etoposide as your first treatment
Tecentriq or Tecentriq Hybreza may be used with the medicine lurbinectedin as maintenance treatment when your lung cancer:
has not progressed after first treatment with Tecentriq or Tecentriq Hybreza and the chemotherapy medicines carboplatin and etoposide.
Adults with a type of liver cancer called hepatocellular carcinoma (HCC). Tecentriq or Tecentriq Hybreza may be used with the medicine bevacizumab when your liver cancer:
has spread or cannot be removed by surgery,
and
you have not received other medicines by mouth or injection through your vein (IV) to treat your cancer.
Adults with a type of skin cancer called melanoma. Tecentriq or Tecentriq Hybreza may be used with the medicines cobimetinib and vemurafenib when your melanoma:
has spread to other parts of the body or cannot be removed by surgery,
and
has a certain type of abnormal “BRAF” gene. Your healthcare provider will perform a test to make sure this Tecentriq or Tecentriq
Hybreza combination is right for you.
Adults and children (12 years of age and older), with a type of soft tissue tumor (cancer) called alveolar soft part sarcoma (ASPS). Tecentriq or Tecentriq Hybreza may be used when your sarcoma:
has spread to other parts of the body or cannot be removed by surgery.
Adults with a type of bladder cancer called muscle invasive bladder cancer (MIBC) that has spread into the muscle layer of the bladder but not to other parts of the body. Tecentriq or Tecentriq Hybreza may be used alone as a treatment for your bladder cancer:
to help prevent your bladder cancer from coming back after your bladder has been removed by surgery,
and
small pieces of DNA from the tumor (called circulating tumor DNA [ctDNA]) were found in your blood, showing that cancer cells remain in the body (molecular residual disease). Your healthcare provider will perform a test to make sure that Tecentriq or Tecentriq Hybreza is right for you.
Adults and children with a type of colon cancer (Tecentriq is for children 2 years of age and older; Tecentriq Hybreza is for children 12 years of age and older and who weigh 88 pounds (40kg) or more)
.
Tecentriq or Tecentriq Hybreza
may be used with a fluoropyrimidine and oxaliplatin medicine:
to help prevent your colon cancer from coming back after your tumor(s) have been removed by surgery,
and
you have stage 3 colon cancer, and your tumor has been shown by a laboratory test to be mismatch repair deficient (dMMR).
It is not known if
Tecentriq Hybreza
is safe and effective when used:
in children younger than 12 years of age for the treatment of ASPS or colon cancer.
in children for the treatment of NSCLC, SCLC, HCC, melanoma or MIBC.
It is not known if
Tecentriq
is safe and effective when used:
in children younger than 2 years of age for the treatment of ASPS or colon cancer.
in children for the treatment of NSCLC, SCLC, HCC, melanoma or MIBC.
Important Safety Information
Who should not receive Tecentriq Hybreza?
Do not receive Tecentriq Hybreza if you
are allergic to hyaluronidase or any of the ingredients in Tecentriq Hybreza.
What is the most important information about Tecentriq and Tecentriq Hybreza?
Tecentriq and Tecentriq Hybreza can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.
Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:
Lung problems
cough
shortness of breath
chest pain
Intestinal problems
diarrhea (loose stools) or more frequent bowel movements than usual
stools that are black, tarry, sticky, or have blood or mucus
severe stomach-area (abdomen) pain or tenderness
Liver problems
yellowing of your skin or the whites of your eyes
severe nausea or vomiting
pain on the right side of your stomach area (abdomen)
dark urine (tea colored)
bleeding or bruising more easily than normal
Hormone gland problems
headaches that will not go away or unusual headaches
eye sensitivity to light
eye problems
rapid heartbeat
increased sweating
extreme tiredness
weight gain or weight loss
feeling more hungry or thirsty than usual
urinating more often than usual
hair loss
feeling cold
constipation
your voice gets deeper
dizziness or fainting
changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
Kidney problems
decrease in your amount of urine
blood in your urine
swelling of your ankles
loss of appetite
Skin problems
rash
itching
skin blistering or peeling
painful sores or ulcers in your mouth or your nose, throat, or genital area
fever or flu-like symptoms
swollen lymph nodes
Problems can also happen in other organs.
These are not all of the signs and symptoms of immune system problems that can happen with Tecentriq or Tecentriq Hybreza. Call or see your healthcare provider right away for any new or worsening signs or symptoms, including:
Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles
Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
Persistent or severe muscle pain or weakness, muscle cramps
Low red blood cells, bruising
Infusion reactions that can sometimes be severe or life-threatening.
Signs and symptoms of infusion reactions may include:
chills or shaking
itching or rash
flushing
shortness of breath or wheezing
dizziness
feeling like passing out
fever
back or neck pain
Rejection of a transplanted organ or tissue.
Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ or tissue transplant that you have had.
Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).
These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with Tecentriq or Tecentriq Hybreza. Your healthcare provider will monitor you for these complications.
Getting medical treatment right away may help keep these problems from becoming more serious.
Your healthcare provider will check you for these problems during your treatment with Tecentriq or Tecentriq Hybreza. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with Tecentriq or Tecentriq Hybreza if you have severe side effects.
Before you receive Tecentriq or Tecentriq Hybreza, tell your healthcare provider about all of your medical conditions, including if you:
have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
have received an organ or tissue transplant, including corneal transplant
have received or plan to receive a st
Contacts
Media Contact: Stella Belonwu, (650) 467-6800
Advocacy Contact: Catherine Creme Henry, (202) 258-8828
Investor Contacts: Loren Kalm, (650) 225-3217
Bruno Eschli, +41 61 68-75284
Read full story here
